BioCentury
ARTICLE | Clinical News

OncoMethylome gains on CRC data

September 22, 2009 1:11 AM UTC

OncoMethylome Sciences S.A. (Euronext:ONCOB) gained EUR 0.63 (11%) to EUR 6.60 on Monday after reporting that its blood-based colorectal cancer screening test had 58% sensitivity and 90% specificity for methylated spectrin repeat containing nuclear envelope 1 (SYNE1) and Forkhead box E1 (FOXE1) (TTF-2) in a feasibility study of blood samples from 124 colorectal cancer patients and 444 control patients undergoing colonoscopy for cancer screening. The company said it has found a higher frequency of methylated SYNE1 and FOXE1 in blood samples of colorectal cancer patients compared with those of non-cancerous individuals. ...